Agios Bets Commercial Base Against REMS Delay and Thin Sickle Cell Data

Agios Cuts R&D Roles Amid FDA Delay for Sickle Cell Drug

Agios Pharmaceuticals is undergoing a commercial-focused restructuring, cutting over 35% of its R&D team (more than 100 roles) and expecting $11 million in restructuring charges. This strategic shift, viewed favorably by analysts, aims for profitability by 2028. The restructuring follows an FDA delay for its sickle cell disease candidate, mitapivat, pushing the decision from November 1 to February 1, 2027, due to a request for more information on a potential Risk Evaluation and Mitigation Strategy (REMS). The company's strategy now emphasizes commercialization and late-stage rare hematology development, leveraging its mitapivat franchise which generated $55.4 million in Q3 global net revenue.

• Agios Pharmaceuticals is implementing a significant restructuring, reducing its R&D workforce by over 35%, impacting more than 100 employees. This strategic shift is expected to incur approximately $11 million in restructuring charges this year, with anticipated savings realized in 2027, and aims to achieve profitability by 2028, a move positively received by financial analysts.
• The FDA has delayed its decision on Agios's sickle cell disease candidate, mitapivat, from November 1 to February 1, 2027. This delay stems from the agency's request for additional information regarding a potential Risk Evaluation and Mitigation Strategy (REMS) for the drug in this indication, which was considered a major amendment to the application.
• Agios is re-aligning its operating model to focus on commercialization and late-stage rare hematology development, aiming to maximize its mitapivat franchise. This franchise, which includes Pyrukynd for PK deficiency and Aqvesme for thalassemia, generated $55.4 million in global net revenue for the third quarter, surpassing analyst expectations.

Mitapivat's Safety Profile Across Indications and REMS Considerations

Mitapivat was generally well tolerated in adults with pyruvate kinase deficiency who were not receiving regular transfusions. In the uncontrolled phase 2 study in 52 adults, common adverse events including headache and insomnia occurred at drug initiation and were transient, with 92% of headache episodes and 47% of insomnia episodes resolving within 7 days, while hemolytic anemia and pharyngitis each occurred as serious adverse events in 2 patients (4%). In the global phase 3 ACTIVATE trial, the most common adverse events were nausea in 7 patients [18%] in the mitapivat group and 9 patients [23%] in the placebo group and headache in 6 patients [15%] and 13 patients [33%], respectively, with adverse events of grade 3 or higher in 10 patients (25%) who received mitapivat and 5 patients (13%) who received placebo and no new safety signals identified. In ACTIVATE-T in 27 adults receiving regular transfusions with median exposure of 40.3 weeks (IQR 40.0-41.3), the most common treatment-emergent adverse events were increase in alanine aminotransferase (ten [37%] participants), headache (ten [37%]), increase in aspartate aminotransferase (five [19%]), fatigue (five [19%]), and nausea (five [19%]), with two grade 3 treatment-emergent adverse events related to study treatment including joint swelling (one participant [4%]) and increase in aspartate aminotransferase (one participant [4%]), three participants with serious treatment-emergent adverse events none related to study treatment including increased blood triglycerides, ovarian cyst, and renal colic (each in one participant [4%]), and no treatment-related deaths.

In sickle cell disease, mitapivat was well tolerated at multiple ascending doses with mostly mild events and low rates of treatment-related serious events. In the phase 1 dose-escalation study in 16 subjects completing 5, 20, and 50 mg twice daily for 2 weeks each with escalation to 100 mg twice daily in 9 subjects, the most common treatment-emergent adverse events were insomnia, headache, and hypertension, with six serious adverse events including 4 vaso-occlusive crises (VOCs), non-VOC-related shoulder pain, and a preexisting pulmonary embolism, where two VOCs occurred during drug taper and were possibly drug related and no other serious adverse events were drug related. In the 1-year phase 2 open-label follow-up in which 9/10 (90%) patients continued in the fixed-dose extension, mostly mild treatment-emergent adverse events most commonly transaminase increase and headache were reported, with one non-treatment-related serious adverse event of urinary tract infection in the dose-finding period and one non-treatment-related serious adverse event of death from massive pulmonary embolism due to COVID-19 in the extension. In the phase 2 12-week double-blind period of RISE UP in 26 patients on mitapivat 50 mg, 26 on 100 mg, and 27 on placebo twice daily, serious adverse events were reported in two (8%) of 26 patients in the 50 mg group, four (15%) of 26 in the 100 mg group, and three (11%) of 27 in the placebo group, grade 3 or worse adverse events occurred in three (12%), five (19%), and two (7%), respectively, with no serious or grade 3 or worse events considered treatment related and no treatment-related deaths, and the most common grade 3 or worse events were infections and infestations including one placebo patient with infected skin ulcer, one 50 mg patient with meningitis and one with pelvic inflammatory disease, and one patient each with malaria, pneumonia, and tonsillitis in the 100 mg group.

In thalassemia, mitapivat showed a tolerable safety profile consistent with prior studies in other hemolytic anemias with predominantly low-grade events and few discontinuations. In the open-label multicentre phase 2 study in non-transfusion-dependent α-thalassemia or β-thalassemia and its extension to Week 156 in 17 of 20 enrolled patients, five patients (29%) had a grade ≥3 treatment-emergent adverse event with none considered treatment related. In ENERGIZE in adults with non-transfusion-dependent α-thalassemia or β-thalassemia, adverse events were reported in 107 (83%) of 129 patients who received mitapivat and 50 (79%) of 63 who received placebo, most commonly headache (29 [22%] vs six [10%]), initial insomnia (18 [14%] vs three [5%]), nausea (15 [12%] vs five [8%]), and upper respiratory tract infection (14 [11%] vs four [6%]), with no deaths reported. In ENERGIZE-T in 258 randomly allocated adults with transfusion-dependent α-thalassemia or β-thalassemia, adverse events were reported in 155 (90%) treated with mitapivat and 71 (84%) treated with placebo, most commonly headache, upper respiratory tract infection, initial insomnia, diarrhoea, and fatigue with mitapivat, serious adverse events in 19 (11%) and 13 (15%), respectively, discontinuation due to adverse events in ten (6%) who received mitapivat and one (1%) who received placebo, and no deaths reported.

Addressing Key Challenges in Sickle Cell Disease Treatment

Current treatment approaches for sickle cell disease balance symptomatic benefit against limitations in durability, tolerability, curative access, and long-term safety. Evidence supports therapy-specific benefit signals rather than a pooled class-level conclusion, with benefit-risk interpretation needing to distinguish vaso-occlusive morbidity from hemoglobin-centered outcomes and account for replication, durability, and safety completeness.

• Novel pharmacotherapy adherence, persistence and regulatory uncertainty: Real-world studies of l-glutamine emphasize patient adherence and obstacles to medication accessibility and approval as key concerns; the high discontinuation rate and results of the STAND trial led to a significant decrease in the use of crizanlizumab, with postapproval developments including voxelotor withdrawal and regulatory reassessment of crizanlizumab.

• Inconsistent real-world effectiveness and evidence gaps for end-organ outcomes: While some real-world studies have reported a decrease in VOCs and hospitalizations with voxelotor, the results are inconsistent and not conclusive, and further studies are needed to assess the impact of these novel therapies on end-organ-specific complications of SCD.

• Transfusion-related iron overload and chelation burden: Appropriate blood transfusions can both prevent and treat serious complications, but inevitably lead to iron overload and its complications in terms of morbidity and mortality; without correction, iron overload can lead to end-organ damage, resulting in cardiac, hepatic, and endocrine dysfunction/failure, with patient compliance important for effectiveness of iron chelation therapy.

• Transplant limitations in donor availability, toxicity and graft outcomes: Hematopoietic cell transplantation is limited by donor availability and complicated by graft failure, graft versus host disease and prolonged immune suppression, with transplant-related toxicity, non-relapse mortality, infectious complications and secondary malignancies continuing to warrant close follow-up; hydroxyurea and long-term blood transfusions are available but underused.

• Gene therapy manufacturing, conditioning and long-term safety challenges: Challenges include difficulty in obtaining sufficient numbers of autologous hematopoietic stem cell progenitors for genetic manipulation and loss of cells during the manufacturing process, stem-cell mobilisation, toxicity of the conditioning regimens, particularly the sterility induced, fertility preservation, and possible long-term safety including myelodysplastic syndrome and acute myeloid leukemia development after graft rejection and lentivirus-based gene therapy, with accessibility, costs, patient selection, and implementation in high-prevalence regions remaining critical challenges.